If you notice any of these changes, do not inject the medication
In certain embodiments, any controlled-release otic formulation described herein increases the exposure of an active agent and increases the Area Under the Curve (AUC) in otic fluids (e.g., endolymph and/or perilymph) by about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or higher than 100%, compared to an otic formulation that is not a controlled-release otic formulation
Get 15 days of automatic syncing Your current holdings sync automatically for 15 days
Maximum benefits: 12-16 weeks
Koniver attributed these lapses to charting issues and said that no patients were harmed
Clinical Evidence: Promising Results Across Multiple Conditions Celiac Disease: The Pioneer Application The most extensive research on larazotide has been in celiac disease, where it's showing remarkable promise